Results 111 to 120 of about 880,423 (146)

No-observed-adverse-effect level of hair pyrrole adducts in chronic n-hexane intoxication in rats

NeuroToxicology, 2020
n-Hexane has been reported to induce serious peripheral neuropathy in workers. Pyrrole adducts are the unique reaction products of n-hexane in organisms and have been demonstrated to be critical to n-hexane neuropathy. Our previous studies have demonstrated that pyrrole adducts could accumulate in hair and showed high correlation with neuropathy at the
Xianjie Li, Lulu Jiang, Ting Yu, Ming Li, Qiong Wang, Zhidan Liu, Keqin Xie   +6 more
openaire   +2 more sources

Deoxynivalenol at No-Observed Adverse-Effect Levels Aggravates DSS-Induced Colitis through the JAK2/STAT3 Signaling Pathway in Mice

Journal of Agricultural and Food Chemistry, 2023
The etiology of inflammatory bowel diseases (IBDs) involves complex genetic and environmental factors such as mycotoxin contamination. Deoxynivalenol (DON), a well-known mycotoxin, contaminates food and feed and can induce intestinal injury and inflammatory response.
Fang Gan, Ziman Lin, Jiangyu Tang, Xingxiang Chen, Kehe Huang   +4 more
openaire   +2 more sources

The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)

Regulatory Toxicology and Pharmacology, 2005
The no-observed-adverse-effect-level (NOAEL) is an important part of the non-clinical risk assessment. It is a professional opinion based on the design of the study, indication of the drug, expected pharmacology, and spectrum of off-target effects. There is no consistent standard definition of NOAEL. This is based, in part, on the varied definitions of
Michael A, Dorato, Jeffery A, Engelhardt
openaire   +2 more sources

Developmental toxicity of carbendazim: comparison of no-observed-adverse-effect level and benchmark dose approach

Food and Chemical Toxicology, 1998
The benchmark dose (BD) approach has been applied to foetal data from four gavage segment II studies (rat studies 1 and 2, rabbit study, hamster study) on the teratogenic benzimidazole carbendazim. Nineteen parameters were assessed using the log-normal model as a practical tool to derive BDs; good model fitting was observed for all except two ...
A, Mantovani, F, Maranghi, C, Ricciardi, C, Macrì, A V, Stazi, L, Attias, G A, Zapponi   +6 more
openaire   +2 more sources

Evaluation of the No Observed Adverse Effect Level of Solvent Dimethyl Sulfoxide in Drosophila melanogaster

Toxicology Mechanisms and Methods, 2003
Dimethyl sulfoxide, a solvent commonly used in toxicological studies, was investigated for its cytotoxic potential and its effect on development and reproductive performance in transgenic Drosophila melanogaster (hsp70-lacZ) Bg 9. Various concentrations (0.0, 0.1, 0.3, 0.5, 1.0, 2.0, and 3.0%) of the solvent were mixed with food and fed to the flies ...
Aamir, Nazir, Indranil, Mukhopadhyay, D K, Saxena, D Kar, Chowdhuri   +3 more
openaire   +2 more sources

Conversion Factors Estimating Indicative Chronic No-Observed-Adverse-Effect Levels from Short-Term Toxicity Data

Regulatory Toxicology and Pharmacology, 1996
Data on chronic toxicity are generally required to derive a health-based acceptable exposure limit, such as the acceptable daily intake. However, only acute and/or subacute toxicity data are available for many compounds. In this study, we assessed conversion factors (CFs) to estimate a chronic no-observed-adverse-effect-level (NOAELchronic) from these ...
Kramer, HJ, van den Ham, WA, Slob, W, Pieters, MN   +3 more
openaire   +3 more sources

Estimating equivalent human concentrations of no observed adverse effect levels: a comparison of several methods

Experimental Pathology, 1989
Four methods for intra- and inter-species dose extrapolation for inhalation reference doses are discussed. Dichloromethane is used as an example to illustrate quantitative differences in the methods. The methods include a procedure recommended by the U.S.
J H, Overton, A M, Jarabek
openaire   +2 more sources

Incidence of developmental defects at the no observed adverse effect level (NOAEL)

Regulatory Toxicology and Pharmacology, 1992
Bioassay data from Teratology, Vol. 1 (1968) through Vol. 40 (1990), were utilized which were sufficient to establish no observed adverse effect levels (NOAEL's) for 120 experiments on 93 developmental toxicants in animals. The observed incidence (risk) at the NOAEL was calculated as the proportion of affected fetuses minus the proportion affected in ...
openaire   +2 more sources

Statistical issues on the determination of the no‐observed‐adverse‐effect levels in toxicology

Environmetrics, 2001
AbstractThe determination of a safe exposure level for toxic agents, often defined as the highest dose level with no toxic effect and termed the no‐observed‐adverse‐effect level (NOAEL) is reviewed. The conventional methods based on statistical tests are criticized, particularly when the sample size is small, and an alternative method, which is based ...
Takashi Yanagawa, Yasuki Kikuchi
openaire   +1 more source

An updated evaluation of reported no-observed adverse effect levels for chrysotile asbestos for lung cancer and mesothelioma

Critical Reviews in Toxicology, 2016
Although consumption of chrysotile asbestos has decreased since the 1970s, the latency period of asbestos-related cancers is thought to be at least 20-30 years, and therefore the potential health risks associated with historical exposures is still actively researched.
Jennifer S, Pierce, Peter S, Ruestow, Brent L, Finley   +2 more
openaire   +2 more sources